Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Total Liabilities for 7 consecutive years, with $25.7 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 2.8% year-over-year to $25.7 million; the TTM value through Mar 2026 reached $25.7 million, down 2.8%, while the annual FY2025 figure was $23.9 million, 20.92% down from the prior year.
  • Total Liabilities hit $25.7 million in Q1 2026 for Barinthus Biotherapeutics, up from $23.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $34.4 million in Q3 2023 and bottomed at $23.9 million in Q4 2025.
  • Average Total Liabilities over 5 years is $28.5 million, with a median of $28.2 million recorded in 2023.
  • Year-over-year, Total Liabilities soared 227.08% in 2022 and then fell 20.92% in 2025.
  • Barinthus Biotherapeutics' Total Liabilities stood at $27.0 million in 2022, then grew by 1.88% to $27.5 million in 2023, then rose by 9.75% to $30.2 million in 2024, then dropped by 20.92% to $23.9 million in 2025, then increased by 7.49% to $25.7 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $25.7 million, $23.9 million, and $24.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.